A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
The current price of AstraZeneca PLC in the market is 15Β 819,55Β β½, with a 24-hour trading volume of 43,08BΒ β½. The asset's market cap is 24,52TΒ β½, after moving 0.15% in the last day.
Tokenized AstraZeneca PLC is trading at 7Β 759,36Β β½, with a tokenized market cap of 58,19MΒ β½ and a 24-hour trading volume of 50,07MΒ β½. The tokenized asset has moved 1.72% in the past 24 hours.